; ;
Run your own event Donations as a gift Volunteer At work Corporate Partnerships
Participating Hospitals In development Recruiting In follow-up Completed Publications
Aims & Objectives Our Board Advisory Committee Consumer Panel Membership Network International Partners Achievements Publications
donate
Name
Email
Sign up to keep informed

login

TRIALS OPEN TO PATIENT RECRUITMENT


The clinical trials listed in this section are open to patient recruitment. For each trial, an overview of the study design is provided together with a brief explanation of the trial objectives. A more detailed overview is available in the Members Area.

  1. Metastatic Colorectal Cancer | CO.20
  2. Adjuvant Colorectal Cancer | QUASAR 2
  3. Gastrointestinal Stromal Cancer | REGISTER
  4. Rectal Cancer | PETACC 6
  5. Oesophago-Gastric Cancer | ATTAX 3
  6. Operable Gastric

1. Metastatic Colorectal Cancer | CO.20 - Click for Trial Schema

Phase III Randomized Study of BMS-582664 in Combination with Cetuximab (Erbitux®) Versus Placebo in Combination with Cetuximab (Erbitux®) in Patients Previously Treated with Combination Chemotherapy for Metastatic Colorectal Carcinoma.

The CO.20 study is designed to compare the overall survival of patients with previously treated metastatic colorectal carcinoma treated with Brivanib in combination with Cetuximab compared with placebo in combination with Cetuximab. The key question is: Does the addition of an antiangiogenesis inhibitor to standard treatment with an EGFR inhibitor improve the survival of patients with advanced colorectal cancer resistant to all prior chemotherapy regimens?

Principal Investigators
Dr Jeremy Shapiro Medical Oncologist Cabrini Hospital, VIC

Supported by
Bristol-Myers Squibb Company (USA) National Cancer Institute of Canada Clinical Trials Group

2.Adjuvant Colorectal Cancer | QUASAR 2 - Click for Trial Schema

Multi-centre International Study of capecitabine +/- bevacizumab as adjuvant treatment of colorectal cancer.

QUASAR 2 uses a new combination for adjuvant therapy: an oral chemotherapy drug (capecitabine) and a molecularly targeted therapy (bevacizumab), to define whether this is superior in efficacy and less in toxicity than capecitabine alone.

Principal Investigators
Dr Eva Segelov Medical Oncologist St Vincent's Hospital, NSW

Supported by
Roche Products P/L

3.Gastrointestinal Stromal Cancer | REGISTER - Click for Trial Schema

A Phase II, open-label, multicentre, dose escalation trial of imatinib followed by nilotinib in patients who have newly diagnosed, inoperable, gastrointestinal stromal tumour.

This is a Phase II, open label, multicentre study evaluating imantinib dose escalation followed by nilotinib after progressive disease, according to stratification into exon 11 and non-exon 11/WT mutational status. The functional response to therapy, as determined by FDG-PET, will be correlated with pharmacokinetics after administration.

Principal Investigators
Dr. Jayesh Desai Royal Melbourne Hospital, Vic

4.Rectal Cancer | PETACC 6 - Click for Trial Schema

A study of preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer.

The PETACC 6 study is an EORTC-led open-label, randomised, multi-national, two-arm phase III study investigating whether the addition of oxaliplatin to preoperative fluoropyrimidine-based chemoradiation and postoperative fluoropyrimidine-based chemotherapy improves disease-free survival in locally.

Principal Investigators
Dr Timothy Price Medical Oncologist Queen Elizabeth Hospital, SA

5.Oesophago-Gastric Cancer | ATTAX 3

An advanced oesophago-gastric cancer with weekly docetaxel, cisplatin, fluoropyrimidine (w/TCF) plus or minus panitumumab in advanced oesophago-gastric cancer.

The ATTAX3 study is a randomised, phase II study comprising two separate components. Patients with advanced oesophago-gastric cancer will be randomised to receive chemotherapy only (wTCF/X) or chemotherapy plus panitumumab. The study will evaluate the objective tumour response rate of these treatment regimes.

Principal Investigator
Dr Niall Tebbutt, Austin Health, Melbourne

6.Operable Gastric

A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer.

The primary study objective is to investigate whether preoperative chemoradiotherapy leads to improved survival in comparison with preoperative chemotherapy in patients undergoing adequate surgery (D1 dissection) for resectable gastric cancer.

Principal Investigators
A/Prof Trevor Leong, Radiation Oncologist, Peter MacCallum Cancer Centre